The Russian pharmaceutical company Geropharm aims to launch the production of insulin glargine and aspart, alongside genetically engineered drugs containing insulin, at a collaborative facility in the Republic of Azerbaijan by 2025. The country currently imports such drugs from abroad.
At the same time, Geropharm has been hatching plans to start producing insulin in the country for a long time. “An agreement to establish insulin production in Azerbaijan was reached in 2019. This was preceded by the successful testing of our drugs at the Republican Endocrinology Center,” the company clarified.
Before this, another Russian pharmaceutical company, R-Pharm, launched production of a drug in the country to prevent complications of diabetes. According to the terms of the five-year agreement, the plant will produce about 1 million packages per year. According to the Republican Endocrinology Center for 2023, there are more than 320 thousand people diagnosed with diabetes in Azerbaijan, of which about 37% receive insulin.